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Background. Alemtuzumab (Campath-lH) induction with tacrolimus monotherapy has been shown to provide ef-
fective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was 
evaluated in pancreas transplant recipients. 
Methods. Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 20 pancreas after kidney, and 10 
pancreas alone) were carried out under this protocol between July 2003 to January 2005. The mean follow-up was 22 
months (range 17-33). 
Results. One-year patient, pancreas, and kidney allograft survival were 95%, 93%, and 90%, respectively. With 22 
months follow-up, patient, pancreas, and kidney survival were 94%, 89%, and 87%, respectively. The rejection rate was 
30% (18/60), with four patients (7%) experiencing steroid-resistant rejection. Major infection occurred in three (5%) 
patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection. One patient with 
cryptococcal meningitis was successfully treated. Seven (11.7%) patients experienced cytomegalovirus infection, all of 
whom responded to treatment with ganciclovir. One (1.7%) case of polymorphic posttransplant lymphoproliferative 
disease was seen, which regressed with a temporary discontinuation of tacrolimus and high-dose ganciclovir. The mean 
serum creatinine of the 30 simultaneous pancreas-kidney transplants at one year posttransplant was 1.37::!:O.33 mg/ml. 
The preexisting creatinine in pancreas after kidney transplants was not adversely affected by this immunosuppressive 
protocol. 
Conclusion. A single dose of perioperative alemtuzumab followed by daily tacrolimus monotherapy provides effective 
immunosuppression for pancreas transplantation, but the optimal use of this drug combination is not yet clear. 
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(Transplantation 2006;82: 1621-1624) 
Since mid 2001, T cell depletion combined with low-dose 
tacrolimus mono therapy has been used as a standard pro-
tocol for organ transplantation at our center (1). Lymphoid 
depletion with antithymocyte globulin (ATG, Thymoglobu-
lin) in 2001-2002 gave way to alemtuzumab depletion from 
2003 onward after it was demonstrated that alemtuzumab 
(Campath-IH) is a more potent agent with fewer acute side 
effects (2-6). However, the strategy with both antibody prep-
arations was based on the same two therapeutic principles: 
first, reduction of global immune reactivity prior to arrival of 
the allograft, and second, the minimalistic use of posttrans-
plant immunosuppression. The immunologic rationale be-
hind the principles has been reviewed elsewhere (7, 8). 
The co-application of these principles with the combi-
nation of alemtuzumab and tacrolimus monotherapy has 
been demonstrated in our center for liver (9), kidney (10,11), 
lung (12), and small bowel (13) transplantation. It has been 
possible in many of these patients to increase the interval 
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between doses of maintenance tacrolimus monotherapy to 
every two days or even to as long one dose per week. Since 
both the calcineurin inhibitor drugs and prednisone are dia-
betogenic, the potential attractiveness is obvious of a regimen 
that includes both steroid avoidance and minimum exposure 
to tacrolimus. However, in our previous experience with 
A TG-tacrolimus, the risk of rejection of pancreas grafts with the 
institution of space weaning was thought to be greater than that 
to other kinds of organ allografts (1). Consequently, in our early 
experience with pancreas transplantation reported here under 
alemtuzumab-tacrolimus, efforts were not made to space wean 
beyond a one dose per day for atleast one year. Moreover, wean-
ing after one year was not systematically attempted. 
PA.TIENTS AND METHODS 
Immunosuppressive Protocol 
From July 2003 to January 2005, 60 consecutive pri-
mary pancreas transplants were performed under the alemtu-
zumab/tacrolimus monotherapy regimen (30 simultaneous 
pancreas-kidney [SPKs), 20 pancreas after kidney [PAKs], 10 
pancreas alone [PTA]). Follow-up in this group of adults was 
to June 1,2006 with a range of 17-33 months (mean 22). 
The 30 mg alemtuzumab was given perioperative\y 
over two hours. Two grams of methylprednisolone were 
given, one gram as premedication for the alemtuzumab infu-
sion to prevent a cytokine syndrome and the second gram at 
the time of pancreas allograft reperfusion. Twice-daily ta-
crolimus was started orally at day one posttransplant with a 
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12-hr trough target of 10-12 ng/ml. At one year posttrans-
plant, an attempt was made in a few of the stable patients to 
convert to once-a-day tacrolimus with a 24-hr trough target 
of 7-9 ng/ml. Any further reduction oftacrolimus doses was 
guided by clinical status (e.g. infection, posttransplant lym-
phoproliferative disease). 
Antibiotic prophylaxis included routine trimethoprim/ 
sulfamethoxasole (life-long) and nystatin (three months). 
Valganciclovir prophylaxis (450 mg PO daily) was main-
tained for three months postoperatively for cytomegalovirus 
(CMV), except in the CMV seropositive donor to seronega-
tive patients, where it was continued for 12 months. CMV 
antigenemia was performed weekly for the first three months, 
and monthly thereafter. 
Rejection was monitored by routine postoperative amy-
lase and lipase levels. Elevation of these pancreatic enzymes, 
usually twice the baseline, would prompt an ultrasound-
guided biopsy to confirm or refute allograft rejection histo-
logically. Rejection scored as moderate or severe was treated 
with antibody therapy (usually 30 mg Campath IH). Minimal 
or mild acute rejection was treated with steroid boluses. No 
maintenance prednisone was ever added. Steroid resistance, 
as defined as no reduction in lipase levels after two grams of 
intravenous (IV) methylprednisolone for biopsy-confirmed 
rejection, was treated with anti-T cell antibody. In a small 
number of patients, mycophenolate mofetil (MMF; 500 mg 
twice per day) was added temporarily until amylase and lipase 
levels returned to baseline. However, an increase in mainte-
nance tacrolimus to achieve a 12-hr trough above 10 ng/ml 
usually was adequate treatment. 
RESULTS 
Mortality, graft function, and other data are given sep-
arately for SPK, PAK, and PTA in Table 1, and then grouped 
for the following overall analysis of all 60 cases. 
TABLE 1. Breakdown of outcomes in pancreas 
transplant categories 
SPK PAK PTA 
(n=30) (n=20) (n=lO) 
2 2 2 
year year year year year year 
Deaths 2 0 1 0 
Patient survival (%) 97 93 100 95 90 90 
Pancreas loss 3 4 0 1 1 2 
Pancreas survival (%) 90 87 100 95 90 80 
Kidney loss 3 4 0 
Kidney survival (%) 90 87 100 95 
Rejection 9 (30%) 6 (30%) 3 (30%) 
Infection 
Cytomegalovirus 4 (13%) 1 (5%) 2 (20%) 
Cryptococcal meningitis 0 1 (5%) 0 
Human herpesvirus 6 0 1 (5%) 0 
Histoplasmosis 0 0 1 (10%) 
Posttransplant 1 (3%) 0 0 
lymphoproliferative 
disease 
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Patient and Graft Survival 
One-year patient survival was 95%, pancreas graft sur-
vival was 93%, and renal allograft was 90%. With a mean 
follow-up of 22::t9 months (range 17-33 months), patient 
survival was 94%, pancreas graft survival was 89%, and kid-
ney allograft survival was 87%. 
Causes of Patient Death and Graft Loss 
The four patient deaths were due (one each) to dissemi-
nated histoplasmosis (PTA, 3 months), stroke (SPK, 13 months), 
autoimmune hemolytic anemia (SPK, 10 months), and sepsis 
(P AK, 13 months). All four had functioning pancreas grafts at 
the time of death. The three graft losses that occurred without 
patient death were caused (one each) by arterial thrombosis, 
rejection, and a pseudoaneurysm of an extension graft that 
required pancreatectomy. 
Rejection 
The overall rejection rate in this cohort over the entire 
follow-up period was 30%, with rejection episodes occurring 
between 3-18 months posttransplantation. Four patients ex-
perienced pancreas allograft rejection more than one year 
posttransplantation. Of the 18 patients with rejection, 11 
were successfully treated with boluses of methylprednisolone. 
The remaining seven patients with severe or moderate rejec-
tion (n=3) or steroid-resistant rejection (n=4) were treated 
with a second lymphoid depletion (usually another dose of 
Campath-lH). Pancreatic rejection was highly correlated 
with persistently low trough tacrolimus levels, consistent with 
our previous report that early posttransplant pancreas rejec-
tion is rare if the 12-hr tacrolimus trough is ~ 10 ng/ml (14) 
Beyond one year, rejection was uncommon if the tacrolimus 
trough level was above 7 ng/m!. 
Infection and Posttransplant 
Lymphoproliferative Disease (PTLD) 
Severe infection was seen in three (5%) patients, result-
ing in two (3.3%) deaths, one from histoplasmosis and the 
other from a combined CMV /herpes virus (HHV6) infection. 
The third patient had cryptococcal meningitis and was suc-
cessfully treated with antifungal therapy. All seven (11.7%) of 
60 patients in whom cytomegalovirus infection was detected 
by CMV antigenemia were successfully treated with either IV 
gancyclovir or high dose valganciclovir (900 mg orally BID). 
One patient developed Epstein-Barr virus (EBV)-
associated polymorphic PTLD 15 months posttransplant, 
manifested by a small bowel bleed requiring exploration and 
resection. The patient responded to a temporary cessation of 
tacrolimus and high-dose valganciclovir. The patient is now 
two years posttransplantation and doing well with function-
ing allografts on once daily tacrolimus. 
Creatinine 
SPK 
The mean serum creatinine level in the SPK group was 
1.44::tO.32 mg/dl one year posttransplantation and l.37::tO.33 
mg/dl at 18 months. 
PAK 
In the P AK group, the serum creatinine provided by the 
prior renal allografts in 20 recipients was 1.41 ::to.27 mg/dl at 
:(juctlon 
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TABLE 2. Serum creatinine from the time of pancreas 
transplantation (day 0) in PAX patients 
Day 3 6 9 12 > 18 
o months months months months months 
N 20 20 20 
Mean 1.41 1.43 1.50 
SD 0.27 0.36 0048 
P value vs. 0.67 0.13 
dayOa 
a Paired two-tailed Student's t-test. 
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the time of pancreas transplantation. With all but one of the 
20 patients and grafts surviving for 18 subsequent months, 
there was no significant increase in the serum creatinine 
(Table 2). 
PTA 
In the PTA group, the patient who died after three 
months from histoplasmosis was excluded. The serum creat-
inines of the other nine patients are shown individually in 
Figure 1. The slight upward trend in most of these patients 
was ascribed to tacrolimus nephrotoxicity. As expected, the 
nephrotoxicity was most obvious in those with preexisting 
renal dysfunction. 
DISCUSSION 
This experience demonstrated that a single dose of ale-
mtuzumab, followed by tacrolimus monotherapy, provides 
effective immunosuppression for pancreas transplantation. 
The results were consistent with the studies of alemtuzumab 
reported from other centers (15-22) and by us (9-12) in 
which alemtuzumab was combined with various baseline im-
munosuppressants for different other kinds of organ trans-
plantation. In addition to the one and two year patient and 
graft survival, the profile of infectious and other complica-
tions (including the risk of PTLD) in our pancreas recipients 
was similar to that usually reported under conventional mul-
tiple drug immunosuppression. Despite relatively high 12 
and 24 hr drug trough levels, tacrolimus monotherapy used 
in our protocol was relatively free of nephrotoxicity. How-
ever, the optimal timing and dosage of alemtuzumab and 
tacrolimus remain to be determined. 
Wilk! 
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The management policy employed for the 60 recipients 
reported here was strongly influenced by our prior experience 
between July and December 2001 with 14 pancreas recipients 
(10 SPK, 4 PTA) in whom the lymphoid depletion was done 
with a single dose of 5 mg/kg ATG (Thymoglobulin) rather 
than with alemtuzumab (1). In these patients, tacrolimus 
doses were spaced after four or more months to one dose per 
day, every other day, or longer intervals. The "space weaning" 
was associated with a high rate of rejection of the kidney, 
pancreas, or both organs. The diagnosis and management of 
pancreas rejection proved to be particularly difficult. To 
avoid these problems, space weaning, even to the point of one 
dose per day, was avoided throughout the first year in the 
current series. 
With the policy of continuous twice daily tacrolimus 
for the first year, the alemtuzumab-depleted patients re-
ported here had a zero incidence of rejection during the first 
three months. From this time onward, however, 30% of the 
recipients experienced rejection. Efforts to reduce either the 
doses or the dose frequencies of tacrolimus, or to withdraw 
MMF after MMF had been introduced to treat breakthrough 
rejection, were not well tolerated. It appeared that the requi-
site maintenance immunosuppression for these patients was 
fixed at whatever level had been arbitrarily decided upon at 
the outset. Of interest, the late dependence on immunosup-
pression may be more pronounced than that observed in the 
14 ATG-depleted patients of2001 (23). 
The differences between the two series do not consti-
tute a comparison between ATG and alemtuzumab. It has 
been increasingly recognized that alloengraftment/tolerance 
mechanisms can be subverted by the timing and quantity of 
posttransplant immunosuppression thereby contributing to 
the amount of treatment needed chronically (8, 24, 25). With 
this insight, better strategies for the more efficient combined 
use of alemtuzumab and tacrolimus should be possible (25). 
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